Veracyte

About Veracyte

Veracyte is a leading molecular diagnostics company specializing in the development of innovative tests that provide precise, actionable insights for complex diagnostic challenges. Operating at the intersection of genomics and clinical medicine, the company focuses on transforming areas such as thyroid nodules, lung cancer, and other challenging diagnostic categories. Founded in 2000 and headquartered in South San Francisco, California, Veracyte leverages advanced genomic technologies to address unmet needs in diagnostic accuracy and patient care. The company’s flagship product, Envisia Genomic Testing, is a genomic classifier used to assess the risk of fibrotic interstitial lung diseases, while its Afirma Xpression Atlas offers comprehensive genomic profiling for thyroid nodules. These tests are designed to reduce diagnostic uncertainty, minimize invasive procedures, and guide more informed clinical decisions. Veracyte’s solutions primarily target pathologists, pulmonologists, endocrinologists, and other healthcare professionals seeking high-resolution diagnostic tools to improve patient outcomes. Veracyte has established itself as a pioneer in the molecular diagnostics space, with a robust pipeline of tests in development and a strong market presence. The company’s unique value proposition lies in its ability to combine genomic analysis with clinical expertise, delivering tests that are both highly accurate and clinically actionable. By addressing critical diagnostic gaps, Veracyte continues to enhance the standard of care and drive advancements in personalized medicine.